Besins Healthcare Strengthens Drug Delivery Portfolio with UniD Acquisition
Money

Besins Healthcare Strengthens Drug Delivery Portfolio with UniD Acquisition

authorBy T. Harv Eker
DateJul 06, 2026
Read Time2 min

Besins Healthcare has recently expanded its pharmaceutical operations through the acquisition of UniD Manufacturing, a Belgian company renowned for its expertise in long-acting drug delivery technologies. This strategic move aims to bolster Besins Healthcare's capabilities in developing advanced medical solutions.

The acquisition encompasses UniD's facility located in Seraing, Belgium, along with its 52 employees. These employees will transition to Besins Healthcare, where UniD Manufacturing will be rebranded as Besins Healthcare PharmTech. This new entity is set to become a dedicated center for future innovation and development projects, focusing on advanced polymer systems for complex drug delivery formats such as implants and vaginal rings. This integration is expected to significantly enhance the development of drug delivery systems that facilitate less frequent treatment administration.

This collaboration represents a natural partnership, bringing together two teams with extensive and complementary expertise. Both companies express excitement about the future prospects, envisioning continued innovation and service excellence for existing and new clients. While the financial details of the transaction remain undisclosed, UniD Manufacturing will maintain its current operations and client services in the immediate future, with Besins Healthcare continuing its global reach across 114 countries through its 22 subsidiaries, further solidifying its presence in the healthcare industry.

This acquisition marks a pivotal moment for Besins Healthcare, reinforcing its commitment to advancing patient care through innovative drug delivery solutions. By integrating UniD's specialized technologies, the company is poised to make significant strides in developing more effective and convenient treatment options, ultimately improving the quality of life for patients worldwide.

More Articles
Money
Opendoor Stock Dips 21% Amidst Housing Market Challenges and Strategic Shift
Opendoor Technologies (NASDAQ: OPEN) saw its stock decline by 21% in the first half of 2026, as reported by S&P Global Market Intelligence. This downturn follows a period of rapid growth fueled by social media and individual investors, with the company now navigating a challenging housing market. A new CEO, Kaz Nejatian, formerly of Shopify, has implemented a strategic shift focusing on increased transaction volume and faster inventory turnover, moving away from a spread-focused model. Early results show promise, with a significant increase in home acquisitions and faster sales cycles, yet the company remains unprofitable.
By Dave RamseyJul 06, 2026
Money
Semiconductor ETF's Strong Performance in June
The iShares Semiconductor ETF experienced a significant 12.6% increase in June, reflecting a robust period for the semiconductor industry. This growth is attributed to surging demand for AI chips, increased capital spending by manufacturers like Micron Technology, and strategic developments such as Intel's potential chip manufacturing expansion in the U.S. The ETF's diversified portfolio, including major players like Nvidia, Micron, and Intel, allowed investors to capitalize on these varied market drivers. Its strong performance underscores the sector's current vitality and future potential.
By Bola SokunbiJul 06, 2026
Money
Cantor Fitzgerald Boosts Price Target for KLA Corporation (KLAC)
Cantor Fitzgerald has increased its price target for KLA Corporation (KLAC) to $325, citing a robust, multi-generational semiconductor cycle driven by AI infrastructure development. This adjustment reflects a broader industry expectation of significant revenue expansion, with other firms like BofA and Wells Fargo also raising their targets for KLA, highlighting strong confidence in the company's future in the semiconductor and related electronics sectors.
By Vicki RobinJul 06, 2026
Money
Barclays Elevates Price Target for Iron Mountain Amidst AI and Hyperscale Demand
Barclays has increased its price target for Iron Mountain (IRM) to $143, maintaining an Overweight rating. This adjustment reflects heightened growth projections for communications infrastructure REITs, driven by robust hyperscale demand and accelerated enterprise AI adoption. Concurrently, Iron Mountain plans a $1 billion Senior Notes offering to fund revolving credit facility repayments and corporate operations.
By T. Harv EkerJul 06, 2026
Money
Suze Orman's Retirement Wisdom: Preparing for the Unexpected
Financial expert Suze Orman cautions against solely planning to work until age 65, highlighting the risks of involuntary early retirement. She and EBRI Director Craig Copeland offer two key tips for robust retirement planning: prioritize paying off your mortgage and aggressively boost retirement savings in your 50s. This proactive approach helps secure your financial future, regardless of when retirement ultimately begins.
By T. Harv EkerJul 06, 2026